Articles By Ed Miseta

41. A Six-Year Approach To Improving Clinical Trial Efficiencies 5/2/2018

    According to Victoria DiBiaso, global head of clinical operations strategy and collaboration at Sanofi, “When it comes to improving trials, you have to look at protocol optimization. For us, that is where it all begins.

42. Lilly Uses Patient Awareness & Access To Cut Clinical Trial Timelines 5/2/2018

    According to Anne White, Lilly’s VP of next generation development and project management, for the past three years the company has steadily worked toward finding a way to get its medicines to patients faster.

43. Fixing Trials Requires A True Commitment To Patient-Centricity 5/2/2018

    Less than 12 percent of the drugs entering clinical testing will ultimately receive FDA approval. Even representatives of the FDA now admit our process for performing trials is “broken.” 

44. Study Proves Importance Of Patient Diversity In Clinical Trials 3/7/2018

    “The key to fully understanding the safety and efficacy of new medical and device therapies is developing clinical trial databases that adequately reflect the diversity of the U.S. population.”

45. Why All The Talk About Real-World Evidence? 12/7/2017

    In 2017, real-world evidence (RWE) became the topic everyone wanted to discuss. Several executives I have spoken to recently believe it will continue to grow in importance as we move into 2018 and beyond. But why the sudden interest in RWE?

46. Pet Medicines: Smaller Market, Lower Costs, Greater Margins 11/8/2017

    “We have not seen the price escalation that has occurred in clinical trials for human drugs,” says Richard Chin, CEO of KindredBio.

47. Why South Korea Is The Hottest Growth Spot For Clinical Trials 10/10/2017

    “The Korean pharmaceutical industry has been accelerating investments in open innovation and focusing on R&D for entry into overseas markets,” says Deborah Chee, president, Korean National Enterprise for Clinical Trials.

48. Lessons In Collaborating With Big Pharma 9/8/2017

    Any small biopharma knows the importance of collaborating or partnering with larger companies and academic institutions. But where do you start, and who should be involved? And what kind of risk should you take on?

49. Government Funding And Technology: The Right Ticket For Small Pharma 8/9/2017

    Soligenix is a late-stage biopharmaceutical company focused on rare diseases. The company’s president and CEO discusses how government grants and contracts can be one way to help fund research.

50. Genentech Masters Breakthrough Therapy Designation 6/7/2017

    Genentech has garnered 15 Breakthrough Therapy Designations for its medicines since 2013, which is more than any other company. Jeffrey Siegel, senior group medical director for Genentech, believes this success reflects the company’s focus on developing new approaches to address unmet medical needs.